Cortés-Telles A

Language: Spanish
References: 7
Page: 93-94
PDF size: 170.82 Kb.

Text Extraction

No abstract.

REFERENCES

1. García-Zenón T, Villalobos-Silva JA, Trabado-López ME. Neumonía comunitaria en el adulto mayor. Evid Med Invest Salud. 2013; 6: 12-17.

2. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med. 2001; 344: 699-709.

3. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Eng J Med. 2005; 353: 1332-1341.

4. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007; 369: 836-843.

5. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S et al. Drotrecogin alfa (activated) in adults with septic shock. N Eng J Med. 2012; 366: 2055-2064.

6. Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B et al. Recombinant human activated protein c for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med. 2013; 187: 1091-1097.

7. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med. 2013; 41: 580-637.